Glenmark Life Sciences Ltd

Glenmark Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glenmark Life Sciences Ltd

₹ 548 0.91%
02 Jun - close price
glenmarklifesciences.com BSE: 543322 NSE : GLS
About

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.[1]

Key Points

A subsidiary of Glenmark Pharmaceuticals[1]
Glenmark Life Sciences (GLS) is a subsidiary of Glenmark Pharmaceuticals Ltd which launched the API business by setting up a manufacturing facility in 2001 to cater to the growth in the API segment across the world and in 2019, the API manufacturing business of Glenmark was spun off into GLS, which will act as an independent company and focus on API business

Website BSE NSE
  • Market Cap ₹ 6,713 Cr.
  • Current Price ₹ 548
  • High / Low ₹ 564 / 369
  • Stock P/E 14.4
  • Book Value ₹ 175
  • Dividend Yield 3.83 %
  • ROCE 29.9 %
  • ROE 22.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is providing a good dividend yield of 3.83%.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 30.4%
  • Company has been maintaining a healthy dividend payout of 38.9%

Cons

  • Working capital days have increased from 112 days to 175 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
397 521 500 467 525 562 522 514 490 509 541 621
259 394 345 297 364 394 376 372 343 366 395 415
Operating Profit 138 127 155 170 160 167 146 142 147 144 145 206
OPM % 35% 24% 31% 36% 31% 30% 28% 28% 30% 28% 27% 33%
2 0 0 0 4 2 4 5 9 10 7 3
Interest 23 22 22 21 21 7 0 0 0 0 0 0
Depreciation 8 8 8 8 9 10 10 10 10 10 11 12
Profit before tax 108 97 125 141 135 153 140 138 146 144 141 198
Tax % 25% 25% 25% 26% 25% 24% 26% 28% 26% 26% 26% 26%
Net Profit 81 72 93 105 101 115 104 99 109 107 105 146
EPS in Rs 413.60 369.73 476.30 106.81 9.36 9.40 8.46 8.07 8.87 8.72 8.57 11.95
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 886 1,537 1,885 2,123 2,161
0 638 1,064 1,294 1,506 1,519
Operating Profit -0 248 473 592 617 642
OPM % -4% 28% 31% 31% 29% 30%
0 -0 11 0 14 29
Interest 0 1 34 88 28 1
Depreciation 0 19 29 33 38 42
Profit before tax -0 228 421 471 565 629
Tax % -4,200% 14% 26% 25% 26% 26%
Net Profit -0 196 313 352 419 467
EPS in Rs -430.00 997.86 1,597.37 358.74 34.17 38.11
Dividend Payout % 0% 0% 0% 0% 61% 55%
Compounded Sales Growth
10 Years: %
5 Years: 513%
3 Years: 12%
TTM: 2%
Compounded Profit Growth
10 Years: %
5 Years: 305%
3 Years: 14%
TTM: 11%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 25%
Return on Equity
10 Years: %
5 Years: 40%
3 Years: 30%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 2 2 2 25 25
Reserves -1 86 400 751 2,030 2,114
0 0 0 0 3 19
1 1,387 1,324 1,244 414 545
Total Liabilities 0 1,475 1,726 1,997 2,471 2,702
0 456 546 573 595 793
CWIP 0 80 11 14 92 49
Investments 0 0 0 0 0 0
0 939 1,169 1,410 1,784 1,860
Total Assets 0 1,475 1,726 1,997 2,471 2,702

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-0 10 195 388 598 313
0 -9 -51 -69 -122 -154
0 1 -137 -214 -79 -388
Net Cash Flow 0 2 8 106 397 -228

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 44 185 152 120 116 136
Inventory Days 162 441 227 214 185 217
Days Payable 41 201 111 92 110 143
Cash Conversion Cycle 165 424 268 241 190 211
Working Capital Days -2,059 -186 -37 12 150 175
ROCE % 529% 186% 97% 42% 30%

Shareholding Pattern

Numbers in percentages

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
82.84 82.85 82.85 82.85 82.85 82.85 82.85
8.03 8.32 8.12 7.58 6.04 4.45 3.28
0.46 0.47 0.56 0.79 0.79 0.08 0.00
8.67 8.36 8.47 8.78 10.31 12.62 13.86

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls